The big fund selling makes sense explaining the weakness over the last few weeks. I wonder WHY a major shareholder for an exntended period would re-evaluate their position size. It can't be liquidity issues i.e. they need to raise cash as there have to be easier/quicker ways to raise cash selling more liquid stocks.
Maybe a little housekeeping? Selling a stock that they have a loss in for tax reasons? Seems a little early for that though.
Officer/director holdings are as of today and include restricted stock and options, whether or not vested. Institutional holdings are as reported on the most recent Form 13G filing; unless otherwise indicated, the most recent Form 13G filing is for holdings as of 12/31/08 .
The percentages shown below are based on 49.1M diluted shares (#msg-42163809), and hence they differ from the percentages reported in SEC filings.]
Shares Stake Novartis 4,708,679 9.6% T Rowe Price 4,468,373‡ 9.1% Visium Asset Mgmt 3,349,122 6.8% Samana Capital 2,109,760 4.3% Federated Investors 1,381,457† 2.8% R. Langer (Ex-director) 1,066,022 2.7% Craig Wheeler (CEO) 987,344 2.0% Alan Crane (Director) 652,202 1.3% G. Venkataraman (SVP, R&D) 628,540 1.2% Ram Sasisekharan (Director) 517,344 1.0%
†As of 9/30/09 (from 13G/A filing 10/13/09). ‡As of 10/31/09 (from 13G/A filing 11/10/09).